Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MANUFACTURER CHOICE OF DEVICE TO UNDERGO DESIGN CONTROL INSPECTION "REASONABLE APPROACH," FDAer SAYS; HIMA SETS UP WEB SITE ON DESIGN CONTROL AUDITS

This article was originally published in The Gray Sheet

Executive Summary

A Health Industry Manufacturers Association proposal to allow manufacturers to select which of their devices will be inspected for design controls during the one-year transitional period for the requirements is "a reasonable approach," Robert Ruff, a consumer safety officer in FDA's New Jersey District Office, said at a May 30 agency/industry workshop on design controls in Baltimore.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel